- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03879122
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to systemically treat the disease with androgen deprivation therapy (ADT). However, the disease progresses in virtually all patients to the state of castration resistant prostate cancer (CRPC), with a median time to progression of 24 months. Patients with high volume disease (with either visceral metastasis and/or bone metastasis) exhibit a worse prognosis, with a median clinical progression of 14 months.
Recently, the CHAARTED and STAMPEDE studies demonstrated that the combination of Docetaxel (chemotherapy) and ADT delayed the clinical progression and improved the survival a median of 14 months (17 for high volume patients). Nevertheless, the prognosis of patients with high volume metastatic disease continues to be poor.
Meanwhile the immunotherapy, the use of antibodies that recognize tumoral cells and promote the immune system activity against the cancer, has emerged as a very useful option in many cancers. Among others, the antibodies Nivolumab and Ipilimumab have been approved for the treatment of multiple types of cancer.
In this context, SOGUG (Spanish Oncology Genitourinary Group) has designed this new study "PROSTRATEGY" with the objective of evaluating whether the addition of immunotherapy to chemotherapy and ADT improves the prognosis and survival of patients with high volume metastatic hormone-sensitive prostate cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spain, 08035
- Hospital Universitari Vall D'Hebron
-
Burgos, Spain, 09006
- Hospital Universitario de Burgos
-
Ciudad Real, Spain, 13005
- Hospital General de Ciudad Real
-
Cáceres, Spain, 10003
- Hospital San Pedro de Alcántara
-
Girona, Spain, 17007
- Hospital Universitari de Girona Dr. Josep Trueta
-
Lugo, Spain, 27003
- Hospital Universitario Lucus Augusti
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spain, 28013
- Hospital Ramón y Cajal
-
Sevilla, Spain, 41013
- Hospital Virgen Del Rocio
-
Sevilla, Spain, 41071
- Hospital Virgen Macarena
-
Sevilla, Spain, 41014
- Hospital Nuestra Señora de Valme
-
Toledo, Spain, 45004
- Hospital Virgen De La Salud
-
Valencia, Spain, 46009
- Fundacion Instituto Valenciano de Oncologia
-
Valencia, Spain, 46014
- Consorcio Hospital General Universitario de Valencia
-
Vigo, Spain, 36312
- Hospital Universitario Alvaro Cunqueiro
-
-
Asturias
-
Oviedo, Asturias, Spain, 33011
- Hospital Universitario Central de Asturias
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08908
- Hestia Duran I Reynals
-
Manresa, Barcelona, Spain, 08242
- Hospital Sant Joan de Deu (Althaia Manresa)
-
Sabadell, Barcelona, Spain, 08208
- Hospital de Sabadell
-
-
Cordoba
-
Córdoba, Cordoba, Spain, 14004
- Hospital General, Materno E Infantil Reina
-
-
Islas Baleares
-
Palma De Mallorca, Islas Baleares, Spain, 07198
- Hospital Son Llatzer
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
San Sebastián De Los Reyes, Madrid, Spain, 28072
- Hospital Universitario Infanta Sofía
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Complejo Hospitalario de Navarra
-
-
Valenci
-
Valencia, Valenci, Spain, 46015
- Hospital Arnau de Vilanova
-
-
Vizcaya
-
Bilbao, Vizcaya, Spain, 48013
- Hospital de Basurto
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be at least 18 years of age
- Signed and dated written informed consent, obtained before the performance of any protocol-related procedure.
- Histological or cytological diagnosis of prostate cancer with an elevated PSA level and radiologic evidence of metastatic disease.
- ECOG performance-status score of 0, 1, or 2. Patients with a score of 2 are eligible if the decrement in functioning was due to prostate cancer.
- Metastatic disease that has spread beyond the prostate or relapsed after local therapy, documented by body CT scan and/or bone scan, according to PCWG 3 criteria, with high volume according to criteria used in the CHAARTED study.
Radiological and scintigraphic studies to identify initial evaluable disease should be done as follows:
- If ADT has not been initiated, CT scans and bone scan must be obtained within 6 weeks prior to the start of ADT.
- If all required imaging had not been completed prior to starting ADT, any additional scan must be obtained after starting androgen deprivation but prior to randomization and the initiation of docetaxel (It is assumed that the scans of patients with high volume disease would not normalize in less than 120 days to the point that a patient would go from "high volume" to "low volume").
- Measurable or evaluable disease according to the PWGC 3.
- Patients who started ADT for metastatic disease are eligible if ADT commenced within 120 days before randomization, they have not started docetaxel chemotherapy yet, and there was no evidence of clinical, radiological or biochemical progression after ADT.
Patients receiving ADT in the adjuvant and/or neoadjuvant setting for less than 30 months of therapy, AND the effect of the last depot injection had expired at least 12 months prior to documentation of metastatic disease, AND
- They had no evidence of disease (PSA < 0.2 ng/dL) after prostatectomy plus hormonal therapy, or
- PSA was < 0.5 ng/dL after completing radiation therapy plus adjuvant or neoadjuvant hormonal therapy, and had not doubled above nadir in at least 12 months.
Patients must have adequate organ function within 4 weeks prior to randomization and evidenced by:
- Absolute Neutrophil Count > 1500/mm 3
- Platelet count > 100,000/mm 3
- Creatinine clearance (CrCl)> 30 mL/min calculated at screening using the Cockcroft- Gault formula: Creatinine clearance for mule (mL/min) = (140- age in years)(body weight in kg)/[72x(serum creatinine in mg/dl).
- Total bilirubin < 1.5 ULN (< 3.0 mg/dl in patients with Gilbert´s Syndrome).
- Prothrombin time or INR and PTT < 1.5 x ULN, except if on therapeutic anti- coagulation in which case the patient can be enrolled if stable and anti-coagulation levels are appropriate for their condition per good clinical practice.
- ALT and AST < or = 3 x ULN (or < or = 5 if liver metastases)
- At least 4 weeks should have passed after major surgery prior to randomization, and the patient should be recovered from all side effects and complications.
- Men who are sexually active with WOCBP must agree to follow instructions for methods of contraception for the duration of treatment with study drug plus 5 half-lives of study drug plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion.
Exclusion Criteria:
- Patients are not eligible if the PSA has risen from its lowest point, between the beginning of androgen deprivation therapy and the date of randomization, and met criteria for progression as defined in the protocol.
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, PROSTVAC, Sipuleucel-T or any previous immunotherapy or vaccines for cancer.
- Prior chemotherapy in the adjuvant or neoadjuvant setting.
- Unable to receive docetaxel at full doses at investigator criteria.
- Peripheral neuropathy grade > 1.
- All toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia or fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug. Subjects with toxicities attributed to prior surgery or radiotherapy, which are not expected to resolve and result in long-term lasting sequelae, are permitted to enrol.
- History of hypersensitivity reaction to Docetaxel®, other drugs formulated with polysorbate 80, or monoclonal antibodies.
- Prior hormone therapy or immunotherapy in the metastatic setting.
- Prior palliative radiation therapy within 30 days of starting docetaxel.
- Known acute or chronic HIV, Hepatitis B, or Hepatitis C. Past Hepatitis B infection with no signs of activity later, are allowed
- Active brain metastases or leptomeningeal metastases, except if they have been treated and there is a magnetic resonance imaging (or CT scan if MRI were contraindicated) showing no evidence of progression for at least 4 weeks after the treatment
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days previous to randomization. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are allowed.
- Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within the previous six months
- History of malignancy in the past 5 years except for basal cell and squamous cell carcinoma of the skin and non-muscle-invasive bladder cancer. Other more malignancies considered to have a low potential to progress may be enrolled if approved by study chair.
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
- Participation in another clinical trial within 30 days prior to randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ADT + Docetaxel
ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
|
Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2. In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.
Androgen deprivation therapy per the standard of care
|
Experimental: ADT + Docetaxel + Nivolumab
ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
|
Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2. In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.
Androgen deprivation therapy per the standard of care
Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses.
Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
Other Names:
|
Experimental: ADT + Ipilimumab / Docetaxel + Nivolumab
ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
|
Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2. In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.
Androgen deprivation therapy per the standard of care
Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses.
Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
Other Names:
Ipilimumab will be administered on day 1 of each cycle every 3 weeks.
In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue.
Patients should receive 2 doses of ipilimumab (6 weeks).
It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel.
Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: through study completion, an average of 2 years
|
Overall Survival
|
through study completion, an average of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSA response
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
PSA progression-free survival (PSA-PFS)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Radiological progression-free survival (rPFS)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Clinical progression-free survival (cPFS)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Time to castration resistant prostate cancer (TCRPC)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Immune radiological progression-free survival (irPFS)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Immune clinical progression-free survival (icPFS)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Time to immune castration resistant prostate cancer (TiCRPC)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Symptomatic skeletal-related event free survival (SSREFS)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Toxicity of each of the treatment arms by assessing Adverse Events
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Quality of life (QOL)
Time Frame: through study completion, an average of 2 years
|
EQ-5D Questionnaire
|
through study completion, an average of 2 years
|
Quality of life (QOL)
Time Frame: through study completion, an average of 2 years
|
FACT-P Questionnaire
|
through study completion, an average of 2 years
|
Quality of life (QOL)
Time Frame: through study completion, an average of 2 years
|
BPI Questionnaire
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jose Ángel Arranz Arija, MD, PhD, Physician - Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Hypersensitivity
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Docetaxel
- Nivolumab
- Ipilimumab
- Androgens
Other Study ID Numbers
- CA209-9HX
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Hormone-sensitive Prostate Cancer
-
The First Affiliated Hospital with Nanjing Medical...RecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)China
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...European Institute of Oncology; ASST Santi Paolo e CarloRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Italy
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Washington University School of MedicineBristol-Myers Squibb; The Foundation for Barnes-Jewish Hospital; Bavarian Nordic and other collaboratorsCompletedMetastatic Hormone-Sensitive Prostate CancerUnited States
-
Peng Wang, MD PhDWithdrawnMetastatic Hormone-Sensitive Prostate CancerUnited States
-
Astellas Pharma Global Development, Inc.CompletedProstate Cancer | Metastatic Hormone-sensitive Prostate CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingChemotherapy Effect | Metastatic Prostate Cancer | Hormone Sensitive Prostate CancerChina
-
Universitaire Ziekenhuizen KU LeuvenRecruitingProstate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis | Oligometastatic Disease | Hormone Sensitive Prostate CancerBelgium
-
Royal Marsden NHS Foundation TrustJanssen, LPRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)United Kingdom
-
Jena University HospitalBayerRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Germany
Clinical Trials on Docetaxel
-
Nereus Pharmaceuticals, Inc.CompletedCancerUnited States, Australia, India, Chile, Brazil, Argentina
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Zhuhai Beihai Biotech Co., LtdCompletedSolid Tumours | Bioequivalence | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedNon-Small Cell Lung Cancer (NSCLC)China
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnCarcinoma, Non-Small-Cell Lung
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungJapan
-
SanofiCompleted
-
SanofiCompletedLung NeoplasmsFrance, Netherlands, Spain, Turkey, Belgium, Finland, Italy, United Kingdom